Clinical trial
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple…
NCT00340834 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00340834 |
|---|---|
| Title | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase |
| Official title | A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting… |
| Acronym | TRANSFORMS |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg |
| Enrollment | 1,292 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jun 21, 2006 |
| Last update posted | Sep 21, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Egypt, France, Germany, Greece, Hungary, Italy and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: